We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Identification and Analysis of Immunomodulatory Molecules in Patients With Hematologic Disorders and Healthy Volunteers

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00223483
First Posted: September 22, 2005
Last Update Posted: September 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
VA Office of Research and Development
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio
  Purpose
This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

Condition Intervention
Hematologic Diseases Healthy Volunteers Genetic: Isolation of genomic DNA

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Prospective
Official Title: Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers

Resource links provided by NLM:


Further study details as provided by The University of Texas Health Science Center at San Antonio:

Primary Outcome Measures:
  • Repository collection of plasma and serum for future analysis. [ Time Frame: 12 years ]

Biospecimen Retention:   Samples With DNA
Whole blood, serum, white cells

Estimated Enrollment: 1000
Study Start Date: March 2005
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
Intervention Details:
    Genetic: Isolation of genomic DNA
    One time blood draw
Detailed Description:
This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic and community samples
Criteria

Inclusion Criteria:

  • Must be able to give blood
  • Must be able to give informed consent
  • Signed, written informed consent

Exclusion Criteria:

  • Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders.
  • Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00223483


Locations
United States, Texas
Department of Veterans Affairs, South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division
San Antonio, Texas, United States, 78229
The University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
VA Office of Research and Development
Investigators
Study Director: Cesar O Freytes, MD The University of Texas Health Science Center at San Antonio
  More Information

Responsible Party: The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT00223483     History of Changes
Other Study ID Numbers: HSC20040268H
First Submitted: September 13, 2005
First Posted: September 22, 2005
Last Update Posted: September 14, 2017
Last Verified: September 2017

Keywords provided by The University of Texas Health Science Center at San Antonio:
Hematologic Diseases
Genomics
Cytokines
Chemokines
Receptors

Additional relevant MeSH terms:
Hematologic Diseases